APTAR PHARMA Provides Unit-Dose Nasal Spray Technology for Treatment of Opioid Overdose

摘要

Louveeiennes, France - Aptar Pharmaannounced that it has provided thedelivery system and regulatory support for Adapt Pharma's Narcan~R which is the first U.S. FDA-approved nasally administered, needle-free, ready-to use medication that can stop or reverse the effects of an opioid overdose.Working together to achieve combination drug-device product compliance and regulatory approvalNarcan~R contains naloxone which is an opioid antagonist. It is marketed in the U.S. for emergency treatment of known or suspected opioid overdose.